摘要
目的探究哌拉西林他唑巴坦联合沙美特罗替卡松对慢性阻塞性肺疾病(COPD)急性加重患者的临床疗效。方法从2022年1月至2024年1月湛江中心人民医院急诊医学科收治的COPD急性加重患者中选取100例作为研究对象,按照随机数字表法设为两组,各50例。对照组应用哌拉西林他唑巴坦,观察组在对照组基础上增加沙美特罗替卡松。对比两组患者临床治疗效果、肺功能情况及炎性因子变化。结果观察组患者临床治疗效果高于对照组,治疗后的肺功能指标均优于对照组,炎性指标IL-6、hs-CRP、TNF-α水平均低于对照组,P<0.05。结论针对COPD急性加重患者采取哌拉西林他唑巴坦联合沙美特罗替卡松治疗,可提升整体疗效,改善患者肺部功能指标,降低炎性因子水平,利于预后。
Objective:To explore the clinical effect of piperacillin tazobactam combined with salmeterol and fluticasone on acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods:From January 2022 to January 2024,100 COPD in acute exacerbation admitted to the emergency medicine department of Zhanjiang Central People's Hospital were studied and separated into the control group(n=50,piperacillin and tazobactam)and the observation group(n=50,salmeterol and fluticasone+piperacillin and tazobactam).The clinical therapeutic effect,pulmonary function and changes of inflammatory factors were compared.Results:The observation group had higher clinical therapeutic effect than the other group,better pulmonary function indexes after treatment,and lower levels of inflammatory indexes IL-6、hs-CRP and TNF-α(P<0.05).Conclusion:Piperacillin-tazobactam+salmeterol-fluticasone in acute exacerbation of COPD can improve the overall curative effect,improve the lung function index,reduce inflammatory factor levels and be beneficial to the prognosis.
作者
孙华
陈康杰
刘炯
Sun Hua;Chen Kangjie;Liu Jiong(Zhanjiang Central People's Hospital,Emergency Medicine Department,Zhanjiang Guangdong 524000,China)
出处
《生命科学仪器》
2024年第6期64-66,共3页
Life Science Instruments
关键词
哌拉西林他唑巴坦
沙美特罗替卡松
慢性阻塞性肺疾病急性加重
肺功能
Piperacillin and tazobactam
Salmeterol and fluticasone
Acute exacerbation of chronic obstructive pulmonary disease
Pulmonary function
